Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
The TNF antagonists adalimumab, infliximab, and etanercept are effective treatments for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, but only adalimumab and infliximab have been found to be efficacious in Crohn's disease. The present studies evaluated the TN...
Ausführliche Beschreibung
Bibliographische Detailangaben
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 131(2009), 2 vom: 15. Mai, Seite 308-16
|
|---|
| 1. Verfasser: |
Kaymakcalan, Zehra
(VerfasserIn) |
|---|
| Weitere Verfasser: |
Sakorafas, Paul,
Bose, Sahana,
Scesney, Susanne,
Xiong, Limin,
Hanzatian, Denise Karaoglu,
Salfeld, Jochen,
Sasso, Eric H |
|---|
| Format: | Online-Aufsatz
|
|---|
| Sprache: | English |
|---|
| Veröffentlicht: |
2009
|
|---|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.)
|
|---|
| Schlagworte: | Comparative Study
Journal Article
Anti-Inflammatory Agents
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Immunoglobulin G
Membrane Proteins
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
Infliximab
mehr...
B72HH48FLU
Adalimumab
FYS6T7F842
Etanercept
OP401G7OJC |
|---|